THP-1 cells Jurkat cells Human lymphocytes (% of control) (% of control) (% of control) Zn2+ [M] Zn2+ Peptide + Zn2+ Peptide + Zn+2+ DTPA Zn2+ Peptide + Zn2+ Peptide + Zn+2+ DTPA Zn2+ Peptide + Zn2+ Peptide + Zn+2+ DTPA Control 100 ± 4.6 100 ± 2.5 99 ± 6.0 100 ± 3.3 100 ± 3.4 95.0 ± 1.4 100 ± 3.2 100 ± 5.1 100 ± 4.3 1012 100 ± 3.2 102 ± 5.2 101 ± 4.6 100± 1.9 105 ± 1.3 97.0 ± 1.2# 99 ± 2.7 98.5 ± 2.2 98.5 ± 2.7 1011 101 ± 1.6 135 ± 10* 104 ± 5.1# 99 ± 3.1 120 ± 3.3* 96.5 ± 1.8# 100 ± 5.1 114.2 ± 3.6* 101.4 ± 2.1# 1010 99 ± 2.7 190 ± 10* 104 ± 4.8# 100 ± 2.8 143 ± 3.4* 96.8 ± 1.4# 100 ± 3.2 158.5 ± 5.6* 100.0 ± 3.7# 109 102 ± 4.7 192 ± 12* 105 ± 3.1# 101 ± 2.6 140 ± 1.6* 94.3 ± 1.2# 100 ± 5.1 154.2 ± 2.9* 99.2 ± 4.5# 108 101 ± 3.8 195 ± 10* 103 ± 4.2# 100 ± 3.6 145 ± 1.4* 95.6 ± 1.4# 101 ± 5.6 155.7 ± 2.1* 101.4 ± 5.8# The cells were treated with Zn2+, peptide (10-10 M) + Zn2+ (10-12 to 10-8 M) or peptide + Zn2+ (10-12 to 10-8 M) + DTPA (5 μM) for 24 h. The control group was grown without any of the above. The results are presented as the mean ± SD of 3 independent experiments. *p<0.01 in comparison with the Zn2+ group; # p<0.01 with peptide + Zn2+ group

Table 2: The effect of DTPA (zinc chelation) on the Zn2+-peptide complex-induced stimulation of cell proliferation.